Advanced Cancer Clinical Trial
Official title:
The COPE Trial: Communication in Oncologist-Patient Encounters
The overall goal of this study is to improve communication between patients with advanced
cancer and their oncologists. A web-based communication intervention will be delivered to
patients to help them to express their negative emotions and elicit empathic responses from
their oncologists.
The specific aims are to:
AIM 1: Develop a web-based intervention that trains patients with advanced cancer to express
their emotional concerns to their oncologists and to request emotional support during
clinical encounters.
AIM 2: Test whether this intervention can increase patient expression of emotional concerns
and requests for emotional support, as well as improve patient affect by decreasing negative
emotions.
Patients will be recruited from the practices of participating oncologists; therefore,
physicians will be enrolled prior to their patients. All medical, surgical and radiation
oncology faculty and hematology/oncology fellows who see patients in the participating
clinics will be eligible for the study. We will also enroll the mid-level providers (i.e.,
physician assistants and nurse practitioners) who work with many of these oncologists and
any third party who comes to clinic with the enrolled patient.
Biweekly, we will present participating physicians with a list of potentially eligible
patients (those with advanced disease) and ask them to identify those who should not be
approached about study participation. Reasons to not approach include dementia or
inappropriate disease staging. Identified patients will receive a letter from their treating
oncologist inviting them to participate in the study about oncologist-patient communication.
Patients who do not wish to be contacted about the study may call a toll-free number to opt
out. If patients do not respond, a research assistant will contact them by telephone several
days prior to their clinic visit, explain the study in detail, and obtain verbal consent to
conduct a phone screener and baseline interview. It is necessary to conduct the screener and
baseline survey prior to obtaining written consent so that staff may determine eligibility
and then initiate study procedures at the upcoming clinic visit, if appropriate.
The baseline survey includes demographic information and several brief scales. Included in
these is the Impact of Events Scale (IES) to determine level of distress, as the COPE study
is interested in the subset of patients who are experiencing emotional difficulty with their
cancer and may be amenable to support in this domain from their provider. The IES is scored
from 0-44, with anything over 8 signifying at least mild levels of distress. Patients who
score 10 or below will be excluded from the study. After completing the survey measures,
arrangements will be made to meet patients in the clinic before their upcoming visit.
The research assistant will meet the patients in clinic, immediately prior to their next
visit, and obtain written informed consent. After engaging in the informed consent process,
the research assistant will place the audio recorder in the exam room, turn it on before the
oncologist enters the room, exit the room, and then turn off the recorder at the end of the
visit. S/he will not be present in the exam room during the visit. Subjects will complete a
survey immediately after the visit to assess affect and quality of communication.
Immediately after the visit, physicians will complete a very brief questionnaire to assess
their perception of the subjects' distress and whether s/he talked about their distress.
Once research assistants determine that participating patients have an appointment with the
same oncologist within 3 months, they will randomly assign subjects to one of four study
arms (Control, CHESS, COPE, or CHESS+COPE), stratified by site and gender. Research
assistants, equipped with laptop computers, will then introduce subjects to the
intervention. For subjects in the Control arm, research assistants will use the intervention
portal to review general Internet search tools (e.g., google). For subjects in the three
intervention arms, research assistants will demonstrate the appropriately modified
intervention website and ensure subjects' abilities to use it. Subjects will be provided
written materials on the use of the website, and instructions will also be sent shortly
afterward by email. The research assistant will call subjects within 7-14 days by phone and
administer a 1-week follow-up survey to assess affect. This process will be repeated until
staff record up to three clinic visits with the patient subject.
Staff will email and call patient subjects between clinic visits to remind them how to
access the intervention website and answer technical questions. Also, research assistants
will remind participants that a member of the study team will meet with them at their
upcoming oncology appointments.
In the last post-visit call with patient subjects, staff will re-administer the IES. Once
patients complete 3 audio-recorded visits, post-visits, and one-week follow-up interviews,
study participation will be complete.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Factorial Assignment, Masking: Open Label
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03181854 -
Randomized Controlled Trial of Integrated Early Palliative Care
|
N/A | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Recruiting |
NCT05045040 -
Empathetic Communication Facilitation Program for Early Initiation of End-of-life Discussions
|
N/A | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03994601 -
An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01393990 -
A Study of LY2228820 in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02857270 -
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Active, not recruiting |
NCT04121676 -
Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03177291 -
Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC
|
Phase 1 | |
Completed |
NCT03980041 -
Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275)
|
Phase 2 | |
Active, not recruiting |
NCT03674567 -
Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab
|
Phase 1/Phase 2 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A | |
Completed |
NCT02778126 -
A Study of Prexasertib (LY2606368) in Participants With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02529553 -
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
Completed |
NCT02507544 -
A Safety and Pharmacokinetic Study of TRX-818 Administered Orally to Patients With Advanced Cancer
|
Phase 1 | |
Completed |
NCT02245204 -
Phase I Studies of Chlorogenic Acid for Injection for Tolerance and Pharmacokinetic of Advanced Cancers
|
Phase 1 | |
Completed |
NCT01583777 -
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
|
Phase 1 | |
Terminated |
NCT01929941 -
An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies
|
Phase 1 |